Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 126 entries
Sorted by: Best Match Show Resources per page
A Case Report of Nonvasculitic Autoimmune Inflammatory Meningoencephalitis with Sensory Ganglionopathy: A Rare Presentation of Sjögren Syndrome.

Case reports in neurological medicine

Peres J, Cruz S, Oliveira R, Santos L, Valverde A.
PMID: 28182102
Case Rep Neurol Med. 2017;2017:5696512. doi: 10.1155/2017/5696512. Epub 2017 Jan 15.

A 68-year-old Caucasian female was admitted to the emergency department with a progressive history of behavioural symptoms and anxiety followed by visual and auditory hallucinations, forgetfulness, and impaired gait in the previous 3 months. On examination she was psychotic...

Cite
Peres J, Cruz S, Oliveira R, et al. A Case Report of Nonvasculitic Autoimmune Inflammatory Meningoencephalitis with Sensory Ganglionopathy: A Rare Presentation of Sjögren Syndrome. Case Rep Neurol Med. 2017;2017:5696512doi: 10.1155/2017/5696512.
Peres, J., Cruz, S., Oliveira, R., Santos, L., & Valverde, A. (2017). A Case Report of Nonvasculitic Autoimmune Inflammatory Meningoencephalitis with Sensory Ganglionopathy: A Rare Presentation of Sjögren Syndrome. Case reports in neurological medicine, 20175696512. https://doi.org/10.1155/2017/5696512
Peres, João, et al. "A Case Report of Nonvasculitic Autoimmune Inflammatory Meningoencephalitis with Sensory Ganglionopathy: A Rare Presentation of Sjögren Syndrome." Case reports in neurological medicine vol. 2017 (2017): 5696512. doi: https://doi.org/10.1155/2017/5696512
Peres J, Cruz S, Oliveira R, Santos L, Valverde A. A Case Report of Nonvasculitic Autoimmune Inflammatory Meningoencephalitis with Sensory Ganglionopathy: A Rare Presentation of Sjögren Syndrome. Case Rep Neurol Med. 2017;2017:5696512. doi: 10.1155/2017/5696512. Epub 2017 Jan 15. PMID: 28182102; PMCID: PMC5274670.
Copy Download .nbib Format: NLM
Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags.

The Canadian journal of hospital pharmacy

Perks W, Iazzetta J, Chan PC, Brouzas A, Law S, Walker SE.
PMID: 28348427
Can J Hosp Pharm. 2017 Jan-Feb;70(1):7-12. doi: 10.4212/cjhp.v70i1.1622. Epub 2017 Feb 28.

BACKGROUND: Sodium phosphate injection is used to treat moderate to severe hypophosphatemia. There have been no published reports documenting the physical compatibility or chemical stability of sodium phosphate injection in IV solutions.OBJECTIVE: To evaluate the physical compatibility and chemical...

Cite
Perks W, Iazzetta J, Chan PC, et al. Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. Can J Hosp Pharm. 2017;70(1):7-12doi: 10.4212/cjhp.v70i1.1622.
Perks, W., Iazzetta, J., Chan, P. C., Brouzas, A., Law, S., & Walker, S. E. (2017). Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. The Canadian journal of hospital pharmacy, 70(1), 7-12. https://doi.org/10.4212/cjhp.v70i1.1622
Perks, William, et al. "Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags." The Canadian journal of hospital pharmacy vol. 70,1 (2017): 7-12. doi: https://doi.org/10.4212/cjhp.v70i1.1622
Perks W, Iazzetta J, Chan PC, Brouzas A, Law S, Walker SE. Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. Can J Hosp Pharm. 2017 Jan-Feb;70(1):7-12. doi: 10.4212/cjhp.v70i1.1622. Epub 2017 Feb 28. PMID: 28348427; PMCID: PMC5358065.
Copy Download .nbib Format: NLM
The protective effects of plasma gelsolin on stroke outcome in rats.

Experimental & translational stroke medicine

Le HT, Hirko AC, Thinschmidt JS, Grant M, Li Z, Peris J, King MA, Hughes JA, Song S.
PMID: 22047744
Exp Transl Stroke Med. 2011 Nov 02;3(1):13. doi: 10.1186/2040-7378-3-13.

BACKGROUND: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity,...

Cite
Le HT, Hirko AC, Thinschmidt JS, et al. The protective effects of plasma gelsolin on stroke outcome in rats. Exp Transl Stroke Med. 2011;3(1):13doi: 10.1186/2040-7378-3-13.
Le, H. T., Hirko, A. C., Thinschmidt, J. S., Grant, M., Li, Z., Peris, J., King, M. A., Hughes, J. A., & Song, S. (2011). The protective effects of plasma gelsolin on stroke outcome in rats. Experimental & translational stroke medicine, 3(1), 13. https://doi.org/10.1186/2040-7378-3-13
Le, Huong T, et al. "The protective effects of plasma gelsolin on stroke outcome in rats." Experimental & translational stroke medicine vol. 3,1 (2011): 13. doi: https://doi.org/10.1186/2040-7378-3-13
Le HT, Hirko AC, Thinschmidt JS, Grant M, Li Z, Peris J, King MA, Hughes JA, Song S. The protective effects of plasma gelsolin on stroke outcome in rats. Exp Transl Stroke Med. 2011 Nov 02;3(1):13. doi: 10.1186/2040-7378-3-13. PMID: 22047744; PMCID: PMC3224589.
Copy Download .nbib Format: NLM
Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient.

Case reports in gastroenterology

Panteris V, Karakosta A, Merikas E, Peros G, Triantafillidis JK.
PMID: 21103242
Case Rep Gastroenterol. 2009 Sep 12;3(3):280-285. doi: 10.1159/000228895.

A case of gastric outlet obstruction accompanied by diffuse gastritis and gastric ulcer due to cytomegalovirus infection is presented. The patient, a woman aged 67 years with a long history of rheumatoid arthritis under immunosuppressive treatment (methotrexate), was admitted...

Cite
Panteris V, Karakosta A, Merikas E, et al. Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient. Case Rep Gastroenterol. 2009;3(3):280-285doi: 10.1159/000228895.
Panteris, V., Karakosta, A., Merikas, E., Peros, G., & Triantafillidis, J. K. (2009). Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient. Case reports in gastroenterology, 3(3), 280-285. https://doi.org/10.1159/000228895
Panteris, Vasileios, et al. "Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient." Case reports in gastroenterology vol. 3,3 (2009): 280-285. doi: https://doi.org/10.1159/000228895
Panteris V, Karakosta A, Merikas E, Peros G, Triantafillidis JK. Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient. Case Rep Gastroenterol. 2009 Sep 12;3(3):280-285. doi: 10.1159/000228895. PMID: 21103242; PMCID: PMC2988918.
Copy Download .nbib Format: NLM
Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus.

Practical radiation oncology

Healy E, Anderson S, Cui J, Beckett L, Chen AM, Perks J, Stern R, Mayadev J.
PMID: 24674320
Pract Radiat Oncol. 2013 Apr-Jun;3(2):e45-53. doi: 10.1016/j.prro.2012.05.009. Epub 2012 Jun 27.

PURPOSE: The use of brass mesh as a bolus is relatively uncommon in postmastectomy chest wall radiation therapy (PMRT). This study aimed to characterize the skin dose effects of using 2-mm fine brass mesh as an alternative to the...

Cite
Healy E, Anderson S, Cui J, et al. Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus. Pract Radiat Oncol. 2012;3(2):e45-53doi: 10.1016/j.prro.2012.05.009.
Healy, E., Anderson, S., Cui, J., Beckett, L., Chen, A. M., Perks, J., Stern, R., & Mayadev, J. (2013). Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus. Practical radiation oncology, 3(2), e45-53. https://doi.org/10.1016/j.prro.2012.05.009
Healy, Erin, et al. "Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus." Practical radiation oncology vol. 3,2 (2013): e45-53. doi: https://doi.org/10.1016/j.prro.2012.05.009
Healy E, Anderson S, Cui J, Beckett L, Chen AM, Perks J, Stern R, Mayadev J. Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus. Pract Radiat Oncol. 2013 Apr-Jun;3(2):e45-53. doi: 10.1016/j.prro.2012.05.009. Epub 2012 Jun 27. PMID: 24674320.
Copy Download .nbib Format: NLM
Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins.

Frontiers in chemistry

Sahm BDB, Peres J, Rezende-Teixeira P, Santos EA, Branco PC, Bauermeister A, Kimani S, Moreira EA, Bisi-Alves R, Bellis C, Mlaza M, Jimenez PC, Lopes NP, Machado-Santelli GM, Prince S, Costa-Lotufo LV.
PMID: 32195221
Front Chem. 2020 Mar 03;8:110. doi: 10.3389/fchem.2020.00110. eCollection 2020.

The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences,...

Cite
Sahm BDB, Peres J, Rezende-Teixeira P, et al. Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins. Front Chem. 2020;8:110doi: 10.3389/fchem.2020.00110.
Sahm, B. D. B., Peres, J., Rezende-Teixeira, P., Santos, E. A., Branco, P. C., Bauermeister, A., Kimani, S., Moreira, E. A., Bisi-Alves, R., Bellis, C., Mlaza, M., Jimenez, P. C., Lopes, N. P., Machado-Santelli, G. M., Prince, S., & Costa-Lotufo, L. V. (2020). Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins. Frontiers in chemistry, 8110. https://doi.org/10.3389/fchem.2020.00110
Sahm, Bianca Del B, et al. "Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins." Frontiers in chemistry vol. 8 (2020): 110. doi: https://doi.org/10.3389/fchem.2020.00110
Sahm BDB, Peres J, Rezende-Teixeira P, Santos EA, Branco PC, Bauermeister A, Kimani S, Moreira EA, Bisi-Alves R, Bellis C, Mlaza M, Jimenez PC, Lopes NP, Machado-Santelli GM, Prince S, Costa-Lotufo LV. Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins. Front Chem. 2020 Mar 03;8:110. doi: 10.3389/fchem.2020.00110. eCollection 2020. PMID: 32195221; PMCID: PMC7062867.
Copy Download .nbib Format: NLM
Correction to: Neonatal bacterial meningitis versus ventriculitis: a cohort-based overview of clinical characteristics, microbiology and imaging.

European journal of pediatrics

Peros T, van Schuppen J, Bohte A, Hodiamont C, Aronica E, de Haan TR.
PMID: 32965578
Eur J Pediatr. 2020 Dec;179(12):1979. doi: 10.1007/s00431-020-03815-0.

This article originally published with all author names incorrectly listed. All author names have now been transposed and appear correctly above.

Cite
Peros T, van Schuppen J, Bohte A, et al. Correction to: Neonatal bacterial meningitis versus ventriculitis: a cohort-based overview of clinical characteristics, microbiology and imaging. Eur J Pediatr. 2020;179(12):1979doi: 10.1007/s00431-020-03815-0.
Peros, T., van Schuppen, J., Bohte, A., Hodiamont, C., Aronica, E., & de Haan, T. R. (2020). Correction to: Neonatal bacterial meningitis versus ventriculitis: a cohort-based overview of clinical characteristics, microbiology and imaging. European journal of pediatrics, 179(12), 1979. https://doi.org/10.1007/s00431-020-03815-0
Peros, Thomas, et al. "Correction to: Neonatal bacterial meningitis versus ventriculitis: a cohort-based overview of clinical characteristics, microbiology and imaging." European journal of pediatrics vol. 179,12 (2020): 1979. doi: https://doi.org/10.1007/s00431-020-03815-0
Peros T, van Schuppen J, Bohte A, Hodiamont C, Aronica E, de Haan TR. Correction to: Neonatal bacterial meningitis versus ventriculitis: a cohort-based overview of clinical characteristics, microbiology and imaging. Eur J Pediatr. 2020 Dec;179(12):1979. doi: 10.1007/s00431-020-03815-0. PMID: 32965578; PMCID: PMC7852874.
Copy Download .nbib Format: NLM
TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.

World journal of gastrointestinal oncology

Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A.
PMID: 31367274
World J Gastrointest Oncol. 2019 Jul 15;11(7):551-566. doi: 10.4251/wjgo.v11.i7.551.

BACKGROUND: Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular...

Cite
Ntavatzikos A, Spathis A, Patapis P, et al. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol. 2019;11(7):551-566doi: 10.4251/wjgo.v11.i7.551.
Ntavatzikos, A., Spathis, A., Patapis, P., Machairas, N., Vourli, G., Peros, G., Papadopoulos, I., Panayiotides, I., & Koumarianou, A. (2019). TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World journal of gastrointestinal oncology, 11(7), 551-566. https://doi.org/10.4251/wjgo.v11.i7.551
Ntavatzikos, Anastasios, et al. "TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer." World journal of gastrointestinal oncology vol. 11,7 (2019): 551-566. doi: https://doi.org/10.4251/wjgo.v11.i7.551
Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol. 2019 Jul 15;11(7):551-566. doi: 10.4251/wjgo.v11.i7.551. PMID: 31367274; PMCID: PMC6657223.
Copy Download .nbib Format: NLM
Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis.

Porto biomedical journal

Peres J, Martins R, Alves JD, Valverde A.
PMID: 32258592
Porto Biomed J. 2017 May-Jun;2(3):81-85. doi: 10.1016/j.pbj.2017.02.002. Epub 2017 Mar 11.

HIGHLIGHTS: Rituximab use in MG patients lead to the reduction of relapses and to a lesser use of immunosuppressive agents in our series.Rituximab use in our MG patients decreased healthcare costs after treatment, comparing to the pre-treatment period.Rituximab is...

Cite
Peres J, Martins R, Alves JD, et al. Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis. Porto Biomed J. 2017;2(3):81-85doi: 10.1016/j.pbj.2017.02.002.
Peres, J., Martins, R., Alves, J. D., & Valverde, A. (2017). Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis. Porto biomedical journal, 2(3), 81-85. https://doi.org/10.1016/j.pbj.2017.02.002
Peres, João, et al. "Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis." Porto biomedical journal vol. 2,3 (2017): 81-85. doi: https://doi.org/10.1016/j.pbj.2017.02.002
Peres J, Martins R, Alves JD, Valverde A. Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis. Porto Biomed J. 2017 May-Jun;2(3):81-85. doi: 10.1016/j.pbj.2017.02.002. Epub 2017 Mar 11. PMID: 32258592; PMCID: PMC6806977.
Copy Download .nbib Format: NLM
Relations Between Interpersonal Hopelessness and Help-Seeking Intentions and Behaviors in Suicidal Individuals.

Crisis

Peros O, Ward-Ciesielski E.
PMID: 34463545
Crisis. 2021 Aug 31; doi: 10.1027/0227-5910/a000815. Epub 2021 Aug 31.

No abstract available.

Cite
Peros O, Ward-Ciesielski E. Relations Between Interpersonal Hopelessness and Help-Seeking Intentions and Behaviors in Suicidal Individuals. Crisis. 2021;doi: 10.1027/0227-5910/a000815.
Peros, O., & Ward-Ciesielski, E. (2021). Relations Between Interpersonal Hopelessness and Help-Seeking Intentions and Behaviors in Suicidal Individuals. Crisis, . https://doi.org/10.1027/0227-5910/a000815
Peros, Olivia, and Ward-Ciesielski, Erin. "Relations Between Interpersonal Hopelessness and Help-Seeking Intentions and Behaviors in Suicidal Individuals." Crisis vol. (2021). doi: https://doi.org/10.1027/0227-5910/a000815
Peros O, Ward-Ciesielski E. Relations Between Interpersonal Hopelessness and Help-Seeking Intentions and Behaviors in Suicidal Individuals. Crisis. 2021 Aug 31; doi: 10.1027/0227-5910/a000815. Epub 2021 Aug 31. PMID: 34463545.
Copy Download .nbib Format: NLM
The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.

Cancers

Sims D, Maranyane HM, Damerell V, Govender D, Isaacs AW, Peres J, Prince S.
PMID: 32098189
Cancers (Basel). 2020 Feb 21;12(2). doi: 10.3390/cancers12020501.

Rhabdomyosarcoma is a highly aggressive malignant cancer that arises from skeletal muscle progenitor cells and is the third most common solid tumour in children. Despite significant advances, rhabdomyosarcoma still presents a therapeutic challenge, and while targeted therapy has shown...

Cite
Sims D, Maranyane HM, Damerell V, et al. The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma. Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020501.
Sims, D., Maranyane, H. M., Damerell, V., Govender, D., Isaacs, A. W., Peres, J., & Prince, S. (2020). The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma. Cancers, 12(2), . https://doi.org/10.3390/cancers12020501
Sims, Danica, et al. "The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020501
Sims D, Maranyane HM, Damerell V, Govender D, Isaacs AW, Peres J, Prince S. The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma. Cancers (Basel). 2020 Feb 21;12(2). doi: 10.3390/cancers12020501. PMID: 32098189; PMCID: PMC7072582.
Copy Download .nbib Format: NLM
Continuous versus intermittent moderate energy restriction for increased fat mass loss and fat free mass retention in adult athletes: protocol for a randomised controlled trial-the ICECAP trial (Intermittent versus Continuous Energy restriction Compared in an Athlete Population).

BMJ open sport & exercise medicine

Peos JJ, Helms ER, Fournier PA, Sainsbury A.
PMID: 30364484
BMJ Open Sport Exerc Med. 2018 Oct 16;4(1):e000423. doi: 10.1136/bmjsem-2018-000423. eCollection 2018.

INTRODUCTION: Reducing fat mass (FM) while retaining fat free mass (FFM) is a common goal of athletes. Evidence suggests that some-but not all-forms of intermittent energy restriction (IER) may be superior to the conventional method of continuous energy restriction...

Cite
Peos JJ, Helms ER, Fournier PA, et al. Continuous versus intermittent moderate energy restriction for increased fat mass loss and fat free mass retention in adult athletes: protocol for a randomised controlled trial-the ICECAP trial (Intermittent versus Continuous Energy restriction Compared in an Athlete Population). BMJ Open Sport Exerc Med. 2018;4(1):e000423doi: 10.1136/bmjsem-2018-000423.
Peos, J. J., Helms, E. R., Fournier, P. A., & Sainsbury, A. (2018). Continuous versus intermittent moderate energy restriction for increased fat mass loss and fat free mass retention in adult athletes: protocol for a randomised controlled trial-the ICECAP trial (Intermittent versus Continuous Energy restriction Compared in an Athlete Population). BMJ open sport & exercise medicine, 4(1), e000423. https://doi.org/10.1136/bmjsem-2018-000423
Peos, Jackson J, et al. "Continuous versus intermittent moderate energy restriction for increased fat mass loss and fat free mass retention in adult athletes: protocol for a randomised controlled trial-the ICECAP trial (Intermittent versus Continuous Energy restriction Compared in an Athlete Population)." BMJ open sport & exercise medicine vol. 4,1 (2018): e000423. doi: https://doi.org/10.1136/bmjsem-2018-000423
Peos JJ, Helms ER, Fournier PA, Sainsbury A. Continuous versus intermittent moderate energy restriction for increased fat mass loss and fat free mass retention in adult athletes: protocol for a randomised controlled trial-the ICECAP trial (Intermittent versus Continuous Energy restriction Compared in an Athlete Population). BMJ Open Sport Exerc Med. 2018 Oct 16;4(1):e000423. doi: 10.1136/bmjsem-2018-000423. eCollection 2018. PMID: 30364484; PMCID: PMC6196972.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 126 entries